Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38−0.07 (-4.83%)
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Inhibikase Therapeutics's price to sales ratio was 229.4× on Oct 31, 2024, against 18.6× a year earlier. Over the last 4 years it ranged from 4.1× to 229.4×, with a median of 21.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Oct 31, 2024 | 229.4× | +208.4 |
| 2023 | Dec 29, 2023 | 21.0× | +16.9 |
| 2022 | Dec 30, 2022 | 4.1× | −8.3 |
| 2021 | Dec 31, 2021 | 12.4× | – |
See a number that looks wrong?